Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Logos Global Management LLC
BioCentury | Mar 11, 2021
Emerging Company Profile
Ventyx emerges with $114M to bring asset-centric immunology plays under one umbrella
Emerging Company Profile: Oppilan, Zomagen and Ventyx merge to advance autoimmune, inflammation pipeline
BioCentury | Jan 8, 2021
Deals
Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more
Cullinan upsizes IPO for $250M raise Cullinan Management Inc. (NASDAQ:CGEM) raised $249.9 million in an IPO via the sale of 11.9 million shares at $21. The company had planned to sell 10 million
BioCentury | Sep 4, 2020
Product Development
Rain to advance growing precision oncology pipeline with $63M series B
A crossover-heavy $63 million series B round will provide Rain with enough money to bring what it says is its new lead program — a newly licensed cancer therapy from Daiichi Sankyo —
Items per page:
1 - 4 of 4